comparemela.com

Latest Breaking News On - Nasdaq sgry - Page 7 : comparemela.com

11,946 Shares in Surgery Partners, Inc (NASDAQ:SGRY) Bought by Fox Run Management L L C

Fox Run Management L.L.C. purchased a new position in Surgery Partners, Inc. (NASDAQ:SGRY – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,946 shares of the company’s stock, valued at approximately $333,000. Several other institutional investors and […]

Surgery Partners (NASDAQ:SGRY) Lifted to Hold at StockNews com

Surgery Partners (NASDAQ:SGRY – Get Rating) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday. SGRY has been the subject of a number of other research reports. Barclays decreased their price target on shares of Surgery Partners from $69.00 to $56.00 […]

Surgery Partners (SGRY) Scheduled to Post Earnings on Monday

Surgery Partners (NASDAQ:SGRY – Get Rating) is set to issue its quarterly earnings data after the market closes on Monday, May 1st. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Surgery Partners has set its FY 2023 guidance at EPS.Individual interested in listening to the company’s earnings conference call […]

Surgery Partners (NASDAQ:SGRY) Shares Gap Up to $37 70

Surgery Partners, Inc. (NASDAQ:SGRY – Get Rating) gapped up prior to trading on Friday . The stock had previously closed at $37.70, but opened at $38.88. Surgery Partners shares last traded at $39.55, with a volume of 156,898 shares traded. Analyst Upgrades and Downgrades Several analysts have issued reports on the stock. Barclays decreased their […]

Cantor Fitzgerald Initiates Coverage on Surgery Partners (NASDAQ:SGRY)

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Surgery Partners (NASDAQ:SGRY – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set an “overweight” rating on the stock. Other research analysts have also recently issued reports about the company. Benchmark reaffirmed a “buy” rating […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.